Literature DB >> 7718190

Imprisonment: a risk factor for HIV infection counteracting education and prevention programmes for intravenous drug users.

R Müller1, K Stark, I Guggenmoos-Holzmann, D Wirth, U Bienzle.   

Abstract

OBJECTIVES: To examine changes of risk behaviour and its determinants as well as risk factors for HIV infection in intravenous drug users (IVDU) with particular attention to imprisonment and its risk patterns.
SETTING: In 1993 a multisite cross-sectional study was carried out by standardized questionnaires and blood/saliva samples in which 612 IVDU from Berlin were enrolled.
RESULTS: Multifactorial analysis revealed that the most important risk factor for HIV infection was needle-sharing in prison. In total, 353 IVDU (58%) reported reduced risk behaviour; changes related more to injection behaviour than sexual practices (91 versus 68%). Important determinants for needle-sharing during the last 6 months were intravenous drug use in prison, duration of drug-taking history, and knowledge of a negative HIV test. The most frequently reported reasons for current needle-sharing were having shared needles with only one regular partner (45%) and imprisonment (26%).
CONCLUSION: Information campaigns and other prevention measures appear to have produced risk awareness in IVDU, and as a consequence, a reduction in risk behaviour. The situation in prisons (no sterile injecting equipment, no effective disinfectants), however, is counteractive to prevention measures implemented outside prisons. An important task for future strategies should be to enable IVDU to avoid HIV transmission while in prisons.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7718190

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  12 in total

1.  A syringe exchange programme in prison as prevention strategy against HIV infection and hepatitis B and C in Berlin, Germany.

Authors:  K Stark; U Herrmann; S Ehrhardt; U Bienzle
Journal:  Epidemiol Infect       Date:  2005-12-22       Impact factor: 2.451

2.  Trends in HIV seroprevalence, AIDS and prevention policy among intravenous drug users and men who have sex with men, before and after 1990 in Austria.

Authors:  F Piribauer; W Duer
Journal:  Eur J Epidemiol       Date:  1998-10       Impact factor: 8.082

3.  Determinants of current HIV risk behaviour among injecting drug users in Warsaw, Poland.

Authors:  K Stark; J Sieroslawski; R Müller; D Wirth; C Godwod-Sikorska; U Bienzle
Journal:  Eur J Epidemiol       Date:  1996-06       Impact factor: 8.082

4.  Needle exchange: panacea or problem?

Authors:  C Hankins
Journal:  CMAJ       Date:  1997-08-01       Impact factor: 8.262

5.  HIV infection in prisons. High risk behaviour is common in prisons in Berlin.

Authors:  R Müller; K Stark; I Guggenmoos-Holzmann
Journal:  BMJ       Date:  1995-05-13

6.  Coinfections by HIV, hepatitis B and hepatitis C in imprisoned injecting drug users.

Authors:  J R Pallás; C Fariñas-Alvarez; D Prieto; M Delgado-Rodríguez
Journal:  Eur J Epidemiol       Date:  1999-09       Impact factor: 8.082

7.  Methadone maintenance treatment and HIV risk-taking behaviour among injecting drug users in Berlin.

Authors:  K Stark; R Müller; U Bienzle; I Guggenmoos-Holzmann
Journal:  J Epidemiol Community Health       Date:  1996-10       Impact factor: 3.710

8.  Predictive factors of HIV-infection in injecting drug users upon incarceration.

Authors:  V Martín; J A Caylà; M L Morís; L E Alonso; R Pérez
Journal:  Eur J Epidemiol       Date:  1998-06       Impact factor: 8.082

9.  Incarceration is a major risk factor for blood-borne infection among intravenous drug users: Incarceration and blood borne infection among intravenous drug users.

Authors:  Mohammad Mehdi Mir-Nasseri; Ashraf Mohammadkhani; Hamid Tavakkoli; Esmaeil Ansari; Hossein Poustchi
Journal:  Hepat Mon       Date:  2011-01       Impact factor: 0.660

10.  The context of HIV risk behaviours among HIV-positive injection drug users in Viet Nam: moving toward effective harm reduction.

Authors:  Duong Cong Thanh; Karen Marie Moland; Knut Fylkesnes
Journal:  BMC Public Health       Date:  2009-04-06       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.